Healthcare, Pharma & Life Sciences

Aroa's Symphony Shows 55% Wound Closure Rate in RCT vs 35%

Image
Aroa's Symphony Shows 55% Wound Closure Rate in RCT vs 35%

Auckland – October 05, 2026 -- Aroa Biosurgery Limited (ASX: ARX) reported that its Symphony wound care product achieved a 55% complete closure rate for diabetic foot ulcers within 12 weeks, compared with 35% for standard of care alone, in a peer-reviewed randomized controlled trial published in the International Wound Journal.

Trial enrolled 143 patients across 10 U.S. sites to test Symphony against standard care

The prospective, multicenter RCT randomized patients with Wagner Grade 1 or 2 diabetic foot ulcers to receive either weekly Symphony plus standard of care or standard of care alone, for up to 12 weeks or until complete closure. Ulcers ranged from full-thickness skin wounds to deeper lesions extending into ligaments, tendons, joint capsules or deep fascia.

Celaid Raises JPY400M as Shionogi, Teikoku Ventures Back US Trial Push

Image
Celaid Raises JPY400M as Shionogi, Teikoku Ventures Back US Trial Push

Tokyo – October 05, 2026 -- Celaid Therapeutics Inc. has completed the second close of its Series B financing round, raising JPY 400 million (approximately USD 2.6 million) with new backing from Shionogi & Co., Ltd. and Teikoku Ventures, Inc.

Shionogi and Teikoku Ventures enter as new strategic investors

The two pharmaceutical-linked investors cited the development progress and therapeutic potential of CLD-001, Celaid's lead hematopoietic stem cell (HSC) therapy candidate, as the basis for their investment. Teikoku Ventures operates as the corporate venture capital arm of the TEIKOKU SEIYAKU Group.

AMED advances Celaid to Stage 3 funding under startup ecosystem program

Celaid also passed the second stage-gate review of AMED's "Strengthening Program for Pharmaceutical Startup Ecosystem,

CSL, Alentis Ink $1.55B Deal for Rare Kidney, Liver Drug

Image
CSL, Alentis Ink $1.55B Deal for Rare Kidney, Liver Drug

Melbourne – October 05, 2026 -- CSL and Alentis Therapeutics have signed an exclusive global collaboration to develop and commercialize lixudebart, a potential first-in-class therapy targeting claudin-1 for rare kidney and liver diseases, with CSL paying Alentis US$355 million upfront and up to US$1.2 billion in commercial milestones.

CSL pays $355 million upfront, commits $1.2 billion in milestone payments

Under the agreement, CSL will fully fund the ongoing Phase 2 RENAL trial, the planned Phase 3 trial in ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), and Phase 2 trials in focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC). Once commercialized, global profits will be split 55 percent to CSL and 45 percent to Alentis.

Ractigen's RAG-18 Shows First Clinical Proof RNA Activation Works in DMD

Hiroshima – October 03, 2026 -- Ractigen Therapeutics presented first-in-human data showing its systemically delivered small activating RNA (saRNA), RAG-18, produced 3.5- to 5.3-fold increases in sarcolemmal utrophin expression in boys with Duchenne muscular dystrophy (DMD), marking the first clinical proof-of-mechanism for RNA activation (RNAa) in a monogenic disease. The data were disclosed in a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society (WMS 2026) in Hiroshima, Japan.

Antengene to Unveil Cos-TCE Platform Data at SITC 2026 in Phoenix

Image
Antengene to Unveil Cos-TCE Platform Data at SITC 2026 in Phoenix

Shanghai/Hong Kong – – October 03, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) will present preclinical results of its novel costimulatory T cell engager (Cos-TCE) platform in a Rapid Oral Abstract Presentation at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2026), running November 4-8 at the Phoenix Convention Center in Arizona.

Chief Scientific Officer to present CD2-based platform data on November 6

Dr. Bing Hou, Antengene's Chief Scientific Officer, will deliver the presentation titled "A CD2-based costimulatory T cell engager platform integrating a novel CD3γε/δε-targeting antibody and steric-hindrance-based CD3 masking," filed under Abstract 15749. The session, categorized as Rapid Oral - Basic 1, is scheduled for 12:30 PM to 1:30 PM Eastern Time on November 6, corresponding to 1:30 AM to 2:30 AM Beijing time on November 7.

XtalPi Advances AI-Designed Hair Loss Drug to IND-Enabling Studies

Image
XtalPi Advances AI-Designed Hair Loss Drug to IND-Enabling Studies

Cambridge/Shenzhen – October 03, 2026 -- XtalPi (HKEX: 2228) has moved its proprietary hair loss drug program into IND-enabling studies, with pharmacology, safety, and chemistry, manufacturing and controls (CMC) work underway to support a future Investigational New Drug application.

Candidate matches minoxidil's efficacy at 1/100 the dose

In a DHT-induced mouse model of androgenetic alopecia, XtalPi's lead candidate achieved a hair-growth score comparable to 5% topical minoxidil while using only one-hundredth of the comparator's concentration. The company also reported preclinical signals of reduced local follicular inflammation, prompting further evaluation of low-concentration topical delivery.

NeuroSense Fights Nasdaq Delisting After Missing $35M Market Value Rule

Image
NeuroSense Fights Nasdaq Delisting After Missing $35M Market Value Rule

Cambridge, Mass. – – October 03, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) received a Nasdaq Staff Determination on October 03, 2026, confirming it failed to meet the $35 million minimum market value of listed securities (MVLS) requirement by its October 03, 2026 deadline, triggering a potential delisting from The Nasdaq Capital Market.

Company to appeal delisting threat before Nasdaq Hearings Panel

NeuroSense intends to timely request a hearing before a Nasdaq Hearings Panel under Nasdaq Listing Rule 5800 Series to seek additional time to regain MVLS compliance. A timely hearing request automatically stays any suspension of trading and the filing of a Form 25-NSE with the SEC while the Panel reviews the case. The Panel has discretion to grant an exception of up to 180 days from the October 1 Staff Determination date.

DisposeRx CEO Warns Medication Safety Gap Persists After Treatment Ends

Image
DisposeRx CEO Warns Medication Safety Gap Persists After Treatment Ends

Southern Pines, N.C. – – October 03, 2026 -- DisposeRx CEO William Simpson is pressing the healthcare industry to extend medication safety protocols beyond the point of prescribing, arguing that leftover drugs left in home medicine cabinets create unmanaged risk once a treatment course concludes.

Simpson says current safety standards stop short of covering the full prescription life-cycle.

In a new commentary, Simpson questions whether the same rigor applied when a patient begins therapy is matched when a condition improves, a dosage changes, one medication replaces another, a physician deprescribes a no-longer-necessary therapy, an antibiotic course ends, or a patient is discharged from the hospital with an altered regimen.

FDA Approves Lilly's Jaypirca as First-Line CLL/SLL Therapy

Image
FDA Approves Lilly's Jaypirca as First-Line CLL/SLL Therapy

Indianapolis – October 03, 2026 -- The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly and Company's Jaypirca (pirtobrutinib), clearing the non-covalent BTK inhibitor as a first-line treatment for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletion.

Phase 3 trial data show an 80% reduction in disease progression risk

The approval rests on the BRUIN CLL-313 trial, which randomized 282 treatment-naïve patients 1:1 to pirtobrutinib or bendamustine plus rituximab (BR) chemoimmunotherapy. At a median follow-up of 28 months, pirtobrutinib cut the risk of disease progression by 80% versus BR (HR=0.20; 95% CI, 0.11–0.37; p0.0001). Median progression-free survival was not yet reached in the pirtobrutinib arm, compared with 33.5 months for BR.

Rice-Backed Duracyte to Trial Implant That Makes Drugs Inside Body

Houston – October 02, 2026 -- Researchers at Rice University, backed by the Rice Biotech Launch Pad, have developed an implantable device that produced therapeutic monoclonal antibodies continuously for one year across multiple preclinical models, with the platform now advancing toward human trials through biotech company Duracyte.

Implant sustained antibody production for a full year in preclinical testing

The system, detailed in a study published in Science Advances titled "Once-yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies," uses engineered protein producers (EPPs) enclosed in a modified biomaterial. The retrievable device also let researchers halt treatment or adjust dosing by removing or replacing the implant, addressing the foreign body response -- inflammation and scar tissue buildup -- that typically limits implanted cell therapy performance.